Akari Therapeutics (AKTX) Non-Current Debt (2017 - 2018)
Akari Therapeutics recorded quarterly Non-Current Debt of $10.0 billion in Q2 2018, little changed quarter-over-quarter from $10.0 billion in Q4 2017.
Akari Therapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $10.0 billion for Q2 2018.
- In Q2 2018, Non-Current Debt changed N/A year-over-year to $10.0 billion; the TTM figure through Jun 2018 stood at $10.0 billion (changed N/A YoY), while the FY2017 annual figure was $10.0 billion, changed N/A from the prior year.
- Non-Current Debt came in at $10.0 billion for Q2 2018 at Akari Therapeutics, roughly flat from $10.0 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $10.0 billion in Q4 2017 to a low of $10.0 billion in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 10.00 Bn |
| Jun 30, 2018 | 10.00 Bn |
| Dec 31, 2017 | 10.00 Bn |
| Dec 31, 2017 | 10.00 Bn |